ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 425

Improving Pneumococcal Vaccination Rates for Immunosuppressed Patients in an Academic Rheumatology Clinic

Alison Bays1, Renuka R. Nayak2, Sara Murray3, Darlene Young4, Gabriela Schmajuk5, Jinoos Yazdany6 and Andrew Gross7, 1Rheumatology, University of Washington, Seattle, WA, 2Rheumatology, UCSF, San Francisco, CA, 3Medicine, UCSF, San Francisco, CA, 4Medicine/Rheumatology, UCSF, San Francisco, CA, 5San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, 6Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 7Medicine/Rheumatology, University of California San Francisco, San Francisco, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Electronic Health Record, immunosuppressants, prevention, Quality improvement and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Quality Measures and Quality of Care - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with autoimmune conditions have higher rates of  pneumococcal disease and they are often immunosuppressed. In 2014, the Advisory Committee on Immunization Practices issued new guidelines recommending vaccination with the 13-valent pneumococcal conjugate vaccine (PCV-13) for immunosuppressed patients. However, only 12% of patients on immunosuppression were vaccinated at our academic referral center. Our aim was to use the Institute for Healthcare ImprovementÕs Model for Improvement to increase the PCV-13 vaccination rate from 12% to 40%.

Methods: Plan-Do-Study-Act (PDSA) methodology was used over 3 cycles within a large rheumatology practice. Patients were eligible for vaccination if they were prescribed disease modifying antirheumatic drugs (DMARDs), biologic agents, or prednisone. Prior to the start of the intervention, vaccination rates were reviewed between 5/1/2014 and 3/1/2015. PDSA Cycles included: (1) Investigator-led educational session for providers regarding risks of pneumococcal disease and benefits of new vaccine (3/1/15 to 5/1/15); (2) Medical assistant (MA) training, utilization of the electronic medical record (EMR) by messaging patients if there was no documentation of their vaccination status prior to visit (5/1/15 to 7/1/15) (3) Creation of a paper form for MAs to complete and indicate patient eligibility followed by MAs writing electronic pended orders, if appropriate. (7/1/15-4/1/16) On a quarterly basis, vaccination rates were abstracted from the EMR (Apex and Clarity) and vaccination rates were tracked using p-charts.

Results: 9 rheumatology fellows, 11 faculty members, 1 nurse practitioner and 9 medical assistants participated in the quality improvement activity. Prior to the intervention, 12% patients had received a PCV-13 vaccination in clinic over a 10-month period. After the third PDSA cycle, over 52% of eligible patients received a PCV-13 vaccination (see Figure).

Conclusion: Targeted education for clinicians and medical assistants in conjunction with using EMR tools for patient reminders and MA-generated orders increased rates of pneumococcal vaccination from 12% to 52% in our large academic rheumatology practice. Ultimately, paper reminders for providers and pended orders by the MAs, in addition to previous interventions, resulted a sustained increase in vaccination rates over a 9-month period without further interventions. Future work will include surveying stakeholders and identifying remaining barriers to vaccination to further increase vaccination rates.


Disclosure: A. Bays, None; R. R. Nayak, None; S. Murray, None; D. Young, None; G. Schmajuk, None; J. Yazdany, None; A. Gross, None.

To cite this abstract in AMA style:

Bays A, Nayak RR, Murray S, Young D, Schmajuk G, Yazdany J, Gross A. Improving Pneumococcal Vaccination Rates for Immunosuppressed Patients in an Academic Rheumatology Clinic [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/improving-pneumococcal-vaccination-rates-for-immunosuppressed-patients-in-an-academic-rheumatology-clinic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-pneumococcal-vaccination-rates-for-immunosuppressed-patients-in-an-academic-rheumatology-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology